Science

We are developing Pan-Amyloid Immunotherapy (PAI), a universal treatment for amyloid-mediated diseases. Our candidates selectively target the conformation present in all amyloid aggregates, making them effective against all amyloid-mediated diseases.

Introducing Pan Amyloid Immunotherapy

Amyl is developing a universal treatment for amyloid-mediated diseases. It’s called
Pan-Amyloid Immunotherapy (PAI), and it will revolutionize our approach to diseases associated with protein misfolding and aggregation.

It’s effective against all protein aggregates of amyloid-mediated diseases and we primarily target neurodegenerative diseases.

It clears amyloid fibrils at the late stage of the disease.

It inhibits early-stage aggregate formation, and dissolves early aggregates.

How Pan Amyloid Immunotherapy (PAI) can treat and prevent amyloid diseases.

Pipeline

We are building an exciting pipeline in systemic and neurodegenerative amyloid-mediated diseases.
‍
Our most advanced clinical candidate is a treatment for a systemic amyloid disease, light chain (AL) amyloidosis. We have demonstrated the proof of concept for neurodegenerative diseases mediated by misfolded amyloid beta, Tau, and Alpha-synuclein. Using novel, AI supported technologies, we are now optimizing the efficacy, efficiency and safety of our molecules.